Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up^†

Affiliations

• ¹ Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (U.L.B), Brussels, Belgium.
• ² Oncology Research Department, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
• ³ Department of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria.
• ⁴ Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
• ⁵ Department of Medical Oncology, National Cancer Center Singapore, Singapore.
• ⁶ Scuola di Medicina, Università Degli Studi Del Piemonte Orientale Amedeo Avogadro, Novara, Italy.
• ⁷ Translational Breast Cancer Genomics Lab - Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
• ⁸ Department of Oncology, Hadassah Medical Center, Jerusalem, Israel.
• ⁹ Department of Medical Oncology, Gustave Roussy - Cancer Campus, Villejuif, France.
• ¹⁰ Breast Cancer Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ¹¹ Centre of Experimental Cancer Medicine, Cancer Research UK Barts Centre, Queen Mary University of London, London, UK.
• ¹² Patient Advocacy, Europa Donna Slovenia, Ljubljana, Slovenia.
• ¹³ Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
• ¹⁴ Medical Oncology Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
• ¹⁵ Department of Obstetrics and Gynecology, Breast Center, LMU Klinikum der Universität München, Munich, Germany.